TLDR: Absci (Nasdaq: ABSI) will release its third quarter 2025 financial and operating results, along with business updates, after market close on Wednesday, November 12, 2025. A conference call and webcast will follow at 4:30 p.m. Eastern Time.
VANCOUVER, Wash. and NEW YORK – Absci (Nasdaq: ABSI), a clinical-stage biotech company leveraging generative artificial intelligence for therapeutic advancements, has announced its plans to report business updates and financial and operating results for the third quarter of 2025. The announcement is scheduled for after market close on Wednesday, November 12, 2025.
Following the release, Absci management will host a conference call and webcast to discuss the company’s business developments, financial and operating results, and future outlook. The call is slated to begin at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Live audio of the webcast will be accessible through the company’s investor relations website at investors.absci.com. For those unable to attend the live event, an archived replay of the webcast will be available on the website after the conference call concludes.
Absci is at the forefront of drug discovery, utilizing generative design to accelerate the creation of superior biologics for patients. Their proprietary Integrated Drug Creation™ platform integrates advanced AI models with a robust synthetic biology data engine. This combination facilitates the rapid design of innovative therapeutics aimed at challenging targets. The company’s methodology is characterized by a continuous feedback loop between sophisticated AI algorithms and rigorous wet lab validation, which continuously refines data and enhances model precision for rapid innovation and therapeutic design accuracy.
In addition to fostering collaborations with leading pharmaceutical, biotech, technology, and academic institutions, Absci is actively developing its own pipeline of AI-designed therapeutics. Key programs include ABS-101, an antibody with the potential to be a best-in-class treatment for inflammatory bowel disease (IBD) and other indications, and ABS-201, a novel solution for hair regrowth that could revolutionize treatments for androgenetic alopecia (male and female pattern baldness).
Also Read:
- Harbour BioMed Unveils Groundbreaking Generative AI Model for Accelerated Biologics Discovery
- Insilico Medicine’s AI Engine Accelerates GLP1R Peptide Design for Diabetes Treatment in Record Time
Absci maintains its headquarters in Vancouver, WA, operates an AI Research Lab in New York City, and has an Innovation Center located in Switzerland.
